1. Scrip
  3. >>Clinical Trials

CTAD 2023: Subcutaneous Leqembi Bests I.V., Could Open Access

At-Home Option An Important Growth Driver for Eisai/Biogen

 
• By Mandy Jackson

The first results for subcutaneous lecanemab in early Alzheimer’s disease show better amyloid clearance with slightly higher ARIA rates than the I.V. version. Eisai also presented Phase III Clarity AD updates and initial long-term extension data.

Alzheimer's disease, Amyloid plaques aggregates, 3d illustration
Amyloid plaque clearance was 14% greater with subcutaneous Leqembi • Source: Shutterstock

Once-weekly subcutaneous injections of Eisai Co., Ltd./Biogen, Inc.’s Leqembi (lecanemab) provided 14% greater amyloid plaque clearance at six months in patients with early Alzheimer’s disease than the US Food and Drug Administration-approved I.V. version of the amyloid protofibril-targeting antibody administered every two weeks. Eisai will submit 12-month results in a biologics license application (BLA) seeking FDA approval for the subcutaneous version by the end of March 2024.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D